ライフサイエンスコーパス: optimal dose

1 weeks, 175 mg/m(2) should be considered the optimal dose.

2 d as both the maximum-tolerated dose and the optimal dose.

3 teness of current designs for identifying an optimal dose.

4 oses in 10 steps starting at 1 : 1000 of the optimal dose.

5 uptake of motexafin gadolinium (MGd) and its optimal dose.

6 he treatment of tuberculosis (TB), is not an optimal dose.

7 aft models, ultimately curing 80% of mice at optimal doses.

8 on, but more research is needed to determine optimal doses.

9 itory than anti-CD154 mAb (100 microg/ml) at optimal doses.

10 ll fusion were enhanced, albeit at different optimal doses.

11 eeded in this area to determine efficacy and optimal dosing.

12 luded in AREDS-type supplements, and at what optimal doses?

13 expended to define chemopreventive activity, optimal dose, administration schedule, and toxicity for

14 To determine the optimal dose, adverse events (AEs), and efficacy of a pe

15 Determining optimal dose and delivery is essential to advance the fi

16 However, the optimal dose and duration are unknown.

17 s who would benefit from prophylaxis and the optimal dose and duration of such prophylaxis should be

18 models of tuberculosis chemotherapy but its optimal dose and exposure in humans are unknown.

19 additional 10 infants receiving the defined optimal dose and for 3 infants receiving placebo.

20 dism require further studies to evaluate the optimal dose and frequency of administration to increase

21 growth dynamics and optimal control theory, optimal dose and frequency of medication customized for

22 ive pulmonary disease (COPD); however, their optimal dose and route of administration are uncertain.

23 in complex concentrates; ambiguity about the optimal dose and route of administration of vitamin K; a

24 However, the optimal dose and safe upper level of zinc have not been

25 The optimal dose and schedule and the appropriate patient po

26 The optimal dose and schedule for cladribine (2CdA) therapy

27 ecommended for routine clinical use, but the optimal dose and schedule for PBSC collection are still

28 resis beginning on day 5 was selected as the optimal dose and schedule for the mobilization of PBPCs.

29 ity associated with the current regimen, the optimal dose and schedule of paclitaxel in combination c

30 The safety and optimal dose and schedule of stem cell factor (SCF) admi

31 However, the optimal dose and the timeframe of administration of C3 a

32 s with acute myocardial infarction (MI), the optimal dose and the timing of its initiation have not b

33 e purpose of this study was to determine the optimal dose and timing of administration of sirolimus (

34 Further studies are needed to determine the optimal dose and timing of IVIG administration.

35 initiated a phase 1/2 study to determine the optimal dose and to assess its efficacy and safety in le

36 addresses key methodological issues, such as optimal dose and treatment duration, are needed.

37 (PK/PD) experiments, and hence the design of optimal doses and dose schedules for the treatment of tu

38 tic potential of these two drugs and predict optimal doses and dose scheduling, it is essential to un

39 studies and first clinical results to select optimal doses and regimens of everolimus to explore in f

40 rther studies will be required to define the optimal doses and schedules for epoetin alfa.

41 National guidelines for optimal doses and timing of vaccines after BMT are warra

42 tations may be useful to select patients for optimal doses and/or modalities of upfront AML therapy.

43 colitis, controversies remain regarding the optimal dosing and delivery systems of the most fundamen

44 Once issues relating to optimal dosing and long-term effects of poloxamer 188 in

45 in-7 (IL-7) can boost CD4 T-cell counts, but optimal dosing and mechanisms of cellular increases need

46 elated laboratory and clinical efficacy, but optimal dosing and monitoring regimens for Africa remain

47 iogenic therapies and determination of their optimal dosing and scheduling.

48 Further studies are needed to determine optimal dosing and the relative ratio of DHA and EPA ome

49 Elucidation of optimal dosing and treatment content is critical for hea

50 se-dependent manner, with 15 mg/kg being the optimal dose (and used in subsequent studies).

51 iological efficacy of exercise, identify the optimal "dose", and pinpoint mechanisms of action.

52 e similarly treated with 0.5 mg simvastatin (optimal dose) and daily intraperitoneal injections of CO

53 We examined specificity of FA, optimal doses, and therapeutic windows for neuroprotecti

54 In sublingual immunotherapy, optimal doses are a key factor for therapeutic outcomes.

55 e safety and efficacy profiles or what their optimal doses are.

56 anations for why antibiotics differ in their optimal dosing are lacking, limiting our ability to pred

57 G(40kd) IFN alpha-2a dose appeared to be the optimal dose based on sustained virological response and

58 ther investigation is warranted to determine optimal dosing based on age and weight.

59 r optimizing antimicrobial use include using optimal dosing based on the manufacturer's instructions

60 t that continued therapy with ruxolitinib at optimal doses contributes to the benefits seen, includin

61 The optimal doses (defined by individual study results) of t

62 tion, including the mechanism of action; the optimal dose; definitive indications; ultimate safety; a

63 In larger tumor, VMAT provided the optimal dose distribution and sparing to heart.

64 uantities of gp96 5-10 times larger than the optimal dose does not elicit tumor immunity.

65 ) mafosfamide was performed to determine the optimal dose, dose-limiting toxicities, and incidence an

66 ss, important questions remain regarding the optimal dose, duration, and mechanisms of action in the

67 ditional research is necessary to assess the optimal dose, duration, and probiotic strain or strains

68 philic leukemia (CEL), little is known about optimal dosing, duration of treatment, and the possibili

69 aximum signal-to-noise ratio (SNR), the mean optimal dose for a 60-min uptake period ranged from 366

70 reclinical and clinical data to identify the optimal dose for an antiangiogenesis agent, anti-EGFL7.

71 reated with dopamine (5.0-7.0 microg/kg/min, optimal dose for contractile increase based on dose-resp

72 rats spinalized as neonates, to identify the optimal dose for improved weight-supported stepping with

73 No epinephrine autoinjectors contain an optimal dose for infants weighing 10 kg or less.

74 The optimal dose for SIT was assessed using efficacy results

75 rvations, the 5 mg/kg dose was chosen as the optimal dose for subsequent behavioral studies.

76 The 400 U dose was recommended as the optimal dose for the phase III trial because of its good

77 erlotinib dose response study to define the optimal dose for the transplantation study.

78 d in tumor-xenografted mice to determine the optimal dose for therapy experiments.

79 Further studies are needed to define the optimal dose for use in combination with other antineopl

80 Optimal dosing for bone health and, possibly, improved s

81 underlying pathomechanisms and identify the optimal dosing for the treatment of patients with this i

82 Optimal dosing frequency, corticosteroid-sparing effect

83 These include the optimal dose, frequency, and duration of methotrexate, a

84 or use in combination regimens; however, the optimal dose has not been defined and final safety and e

85 randomized, controlled trial to evaluate the optimal dose, immunogenicity, safety and immune persiste

86 er than that provided by the therapeutically optimal dose in preclinical studies.

87 However, its optimal dosing in this subgroup has not been studied.

88 dies, using early MPEP treatment (15 min) at optimal doses, infarct volume was reduced by 44% at 72 h

89 The optimal dosing interval for zoledronic acid is uncertain

90 It is also observed that the averaged optimal dose is decreasing as a function of the initial

91 The optimal dose is found by titration and is not predicted

92 y in ST-elevation myocardial infarction, the optimal dose is unclear.

93 ere is an appropriate patient population and optimal dose (LDL concentration) for the treatment of sy

94 Deutetrabenazine or placebo was titrated to optimal dose level over 8 weeks and maintained for 4 wee

95 down designs treated only 35% of patients at optimal dose levels versus 55% for Bayesian adaptive des

96 on of mouse or human RPGR-ORF15 vector at an optimal dose maintained the expression of RPGR-ORF15 thr

97 factor (VEGF).After the establishment of an optimal dose, minocycline treated HASMC were exposed to

98 to review practical guidelines in regard to optimal dosing, monitoring, managing common side effects

99 CY has a narrow therapeutic window, with an optimal dose not exceeding 200 mg/m(2).

100 An optimal dose of 10(7) tissue culture infectious dose 50

101 full length protein to the membrane with an optimal dose of 100 microM in CHO-K1 cells, while diC8 f

102 ventilator-supported patients; however, the optimal dose of a bronchodilator from a MDI is unknown.

103 ease risk through adiposity changes, but the optimal dose of activity is unknown.

104 SON (3.0 mL) compared with only 26% with the optimal dose of ALBUNEX (0.22 mL/kg) (p < 0.001).

105 The optimal dose of aspirin for most clinical situations is

106 was well organized versus that formed by the optimal dose of BMP.

107 ofetil (MMF), it remains unclear what is the optimal dose of CsA beyond the first 6 to 12 months afte

108 t as effective in preventing bone loss as an optimal dose of estrogen.

109 The optimal dose of gB appeared to be between 5 and 30 micro

110 In this work, the optimal dose of glucose oxidase and xylanase were (30 an

111 The optimal dose of granulocyte colony-stimulating factor (G

112 sight into important questions regarding the optimal dose of inhaled nitric oxide, potential adverse

113 The optimal dose of interferon-alfa (IFN) for chronic myeloi

114 rsus MMR(+) normal tissues by predicting the optimal dose of IUdR and optimal timing for IR treatment

115 The optimal dose of IV plerixafor was determined to be 0.32

116 Group B received the optimal dose of O6-BG for 2, 4, 7, or 14 days after surg

117 Data to inform surgeons on the optimal dose of opioids to prescribe after common genera

118 ontrast occurred in 74% of patients with the optimal dose of OPTISON (3.0 mL) compared with only 26%

119 Protocol 9342 was initiated to determine the optimal dose of paclitaxel administered as a 3-hour infu

120 Our data suggest that the optimal dose of perflubron to achieve the lowest oxygena

121 The optimal dose of plasmid vaccine encoding full-length Ag2

122 For the time-window study, the optimal dose of progesterone was given starting at 3, 6

123 The average optimal dose of risperidone in elderly dementia patients

124 The optimal dose of SS1scFvSA for pretargeting was 600 micro

125 The optimal dose of tacrolimus appears to be >1 mg but < or=

126 Determination of the optimal dose of TBI for allogeneic transplantation is co

127 s with solid tumors to define the safety and optimal dose of the combination regimen and to assess ph

128 We sought to determine the optimal dose of the selective endothelin A (ET(A)) recep

129 is required to ensure administration of the optimal dose of unfractionated heparin.

130 Exposure of the rabbit eye in vivo to an optimal dose of UVB produced an increase in the PGE2 lev

131 An optimal dose of WYE-132 achieved a substantial regressio

132 All animals receiving optimal doses of 2H7-Fc-C825 followed by (90)Y-DOTA were

133 evaluable population (n = 39) found that the optimal doses of aldesleukin to induce 10% and 20% incre

134 levels of proliferation upon stimulation by optimal doses of anti-CD3, suggesting the lack of a cost

135 Mice immunized with optimal doses of autologous tumor-derived gp96 resist a

136 sistant schizophrenia who were maintained on optimal doses of clozapine (400-1200 mg/day) were admini

137 Hsp90 release was stimulated with optimal doses of estradiol, IL-1, and TNF-alpha (10 ng/m

138 were obtained in cultures supplemented with optimal doses of FL + IL-7 + IL-3.

139 cts with grass allergen and challenging with optimal doses of grass, birch, recombinant house dust mi

140 Application of sub-optimal doses of morphine in electroacupuncture-treated

141 Immunization with optimal doses of RSV F antigens in the presence of GLA-S

142 ors and indomethacin, and treatment with sub-optimal doses of signal transduction inhibitors, affect

143 Two optimal doses of SS (12.5 and 100 nM) and curcumin (2.5

144 n of Akt to approximately the same extent as optimal doses of wortmannin and LY294002, known inhibito

145 Our report warrants the need to establish optimal dosing of AL in adults and to alert clinicians a

146 Identifying optimal dosing of antibiotics has proven challenging-som

147 Optimal dosing of carboplatin in the high-dose setting w

148 Further studies are needed to determine optimal dosing of CNIs in the elderly.

149 Pharmacokinetic modeling suggested that optimal dosing of eptifibatide would be obtained with a

150 y used successfully to define the safety and optimal dosing of human spinal stem cells after grafting

151 of SSRIs; there is a lack of data regarding optimal dosing of medications for children.

152 Optimal dosing of PRIT plus venetoclax cured 100% of mic

153 Optimal dosing of rabbit antithymocyte globulin (rATG) i

154 Whether patients receive optimal dosing of secondary prevention medications at th

155 ive efficacy in human cancer trials, but the optimal dosing of such agents must still be determined e

156 ditional studies are required to clarify the optimal dosing of tenapanor in patients with CKD-related

157 We sought to identify the optimal dosing of VOR for effective serial reversal of H

158 e was only a slight (1 MBq/kg) dependence of optimal dose on patient weight but a larger dependence o

159 ever, these reports have not established the optimal dosing or ideal timing of the administration of

160 ully ascertain the therapeutic potential and optimal dosing paradigm of a post-ischemic treatment wit

161 owledge of old and new mechanisms of action, optimal doses, pharmacokinetic behavior and drug interac

162 ponsiveness of blood lymphocytes in vitro to optimal dose phytohemagglutinin (PHA) was reduced on day

163 The optimal dosing protocol for rabbit anti-thymocyte globul

164 and warrant further studies to establish the optimal dosing regimen and efficacy.

165 he treatment of pediatric uveitis, including optimal dosing regimen and long-term efficacy.

166 ) effect and the tumor microenvironment, the optimal dosing regimen for carrier-mediated agents, and

167 However, the optimal dosing regimen in settings in which human immuno

168 properties of the drug and to rationalize an optimal dosing regimen in the clinic, a method is needed

169 ents with the higher dosage suggest that the optimal dosing regimen is <50 mg/h.

170 r define the efficacy, long-term safety, and optimal dosing regimen of rituximab in this setting.

171 ill demand strong translational evidence, an optimal dosing regimen, and better tolerability.

172 Studies to investigate the optimal dosing regimen, duration of clinical benefit, an

173 namic behavior of each class of drug so that optimal dosing regimens can be designed.

174 oing clinical trials will help determine the optimal dosing regimens for all of these agents, as well

175 We determined optimal dosing regimens for neutrophil depletion and eva

176 more specific recommendations can be made on optimal dosing regimens for reversal; maintenance; and p

177 tudied with regards to specific indications, optimal dosing regimens, or treatment efficacy.

178 to a therapeutic approach and help establish optimal dose-response curves for training.

179 Trials are needed to determine the optimal dose, route, and duration of octreotide treatmen

180 topotecan may necessitate a reevaluation of optimal dose schedule, with the possible incorporation o

181 inical trials are warranted to determine the optimal dosing schedule of rituximab, the potential for

182 nce and the quantitative model can determine optimal dosing schedule to enhance the effectiveness of

183 uture studies are warranted to determine the optimal dosing schedule to improve therapeutic efficacy

184 intervals in ongoing trials to determine an optimal dosing schedule.

185 The optimal dose, schedule, and number of cycles of postremi

186 been made for radiotherapy but questions of optimal dose, schedule, timing and treatment volume rema

187 Further exploration of the optimal dose/schedule and correlation with biologic end

188 el of intracellular tuberculosis to identify optimal dose schedules and exposures of moxifloxacin and

189 cokinetic studies were encouraged to develop optimal dosing schedules based on therapeutic ranges.

190 During the last four decades, optimal dosing schedules have produced a therapeutic gai

191 population analysis methods, can facilitate optimal dose selection for children and pregnant women.

192 Its optimal dose still needs to be determined.

193 Optimal dosing strategies for SKPT recipients remain to

194 Optimal dosing strategies have not been established for

195 Although used for more than 20 years, optimal dosing strategies of most immunosuppressants hav

196 e still needed to answer questions regarding optimal dosing strategies.

197 The optimal dosing strategy and duration of MMF treatment ha

198 The optimal dosing strategy and feasibility for combination

199 eroids may be of value; safety, efficacy and optimal dosing strategy need prospective appraisal in a

200 The optimal dosing strategy of low-molecular-weight heparins

201 eridol in schizophrenic patients requires an optimal dose that blocks the brain dopamine D2 receptors

202 tro/in vivo PK studies were conducted and an optimal dose that depletes NK cells and NK cell function

203 IT) topotecan was performed to determine the optimal dose, the dose-limiting toxic effects, and the i

204 most appropriate osmotherapeutic agent, the optimal dose, the safest and most effective mode of admi

205 The optimal dose, time to start, and duration of treatment f

206 urther studies are necessary to identify the optimal dose, timing, and route of administration of EGF

207 ped here allows one to directly estimate the optimal dose to inject for specific clinical scans and p

208 e wild-type C57BL/6 animals to determine the optimal dose to test in SR-/- mice.

209 When used in optimal doses to treat patients with heart failure, reni

210 investigation might be aimed at elucidating optimal dosing to minimize adverse events without detrim

211 tients who received 13 days of treatment, at optimal doses, using a biphasic model to describe first-

212 al overall survival rates for patients with "optimal" dose-volume histogram coverage versus "suboptim

213 day achieved a CFR > 90% in infants, but the optimal dose was 20 mg/kg/day in older children.

214 ld allow more patients to be treated at near-optimal doses while controlling for excessive toxicity.

215 f extending continuous-infusion O6-BG at the optimal dose with intracranially implanted carmustine wa

216 may be the most useful method in determining optimal dosing without the risk of disease exacerbation.